STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III TrialCarcinoma

Protocol No
ECOG-EA6174
Principal Investigator
Amy Harker-Murray
Phase
III
Summary
This study is being done to answer the following question: Can we lower the chance of your cancer growing back by adding a study drug after your surgery? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your Merkel Cell Carcinoma. The usual approach is defined as care most people get after surgery to remove the cancer.
Description
Testing Pembrolizumab versus Observation in Patients with Merkel Cell Carcinoma after Surgery
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: